Clinical Trial Results: A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2389 in participants with liver fibrosis and compensated cirrhosis c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Cirrhosis
• Liver Fibrosis

Drugs mentioned

• AZD2389

Snippet

Sponsor: AstraZeneca | Conditions: Liver Fibrosis, Hepatic Cirrhosis | Phase 2 | Status: COMPLETED | Results posted: 2026-07-06